FutureChem Signs CRO Contract for PSMA Mechanism Prostate Cancer Treatment Agent
Published 18 Feb.2020 10:22(KST)
Global CRO 'Linical Excelrobanse' Partners for FC705 Phase 1 Clinical Trial
IND Application for Phase 1 Clinical Trial to be Submitted to MFDS in March... First Patient Dosing Within the Year and Global Clinical Trials to Begin Next Year
[Asia Economy Reporter Eunmo Koo] FutureChem, a company specializing in the development of new radiopharmaceutical drugs, announced on the 18th that it has signed a contract with the clinical research organization (CRO) 'Linical Accelovance' to conduct Phase 1 clinical trials for its prostate cancer treatment radiopharmaceutical FC705.
The company is a global CRO headquartered in the United States, having won the Best CRO award for 11 consecutive years at the Vaccine Industry Excellence Awards (VIE) and has experience conducting large-scale clinical studies in over 20 countries. Notably, it successfully conducted Phase 1 clinical trials for PSMA617, a PSMA mechanism prostate cancer treatment radiopharmaceutical developed in Germany. After the developer Endocyte was acquired by Novartis in 2018, PSMA617 is currently undergoing Phase 3 clinical trials in the United States.
FutureChem plans to conduct clinical trials of FC705 at the Korea Institute of Radiological & Medical Sciences and Seoul St. Mary's Hospital, and after obtaining approval for Phase 1 clinical trials in Korea, it intends to start clinical trials in the United States. According to FutureChem's preclinical results, FC705 shows more than six times higher cancer cell uptake than the competing agent PSMA617, while demonstrating similar therapeutic performance at one-fourth the dosage, suggesting relatively fewer side effects and superior treatment efficacy.
A company representative stated, "We plan to submit an IND (Investigational New Drug application) for FC705 Phase 1 clinical trials to the Ministry of Food and Drug Safety next month," adding, "Our goal is to administer the first patient within this year and to fully launch global clinical trials next year."
FC705 is a radiopharmaceutical labeled with a therapeutic isotope based on the PSMA mechanism. It targets prostate cancer by beta radiation emitted from the radioactive isotope Lutetium-177 (Lu-177), allowing treatment of prostate cancer through multiple injections without surgical intervention.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.